Oddo BHF raises Moderna stock target from USD 170.00 to USD 251.00

Published on 10/21/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock trades at EUR 215.28 on October 21, 2026. Third-quarter results are due November 6, 2026, after Q2 revenue of USD 145.00 million.

Pipeline and reporting dates

Oddo BHF lifted its Moderna target to USD 251.00 on October 19, 2026.
Second-quarter revenue reached USD 145.00 million, up 2.00 percent year over year.
Moderna stock trades at EUR 215.28 at 12:01 p.m. CEST at Lang & Schwarz on October 21, 2026.
Melanoma data are due October 24, 2026, ahead of the November 6, 2026 results.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna stock (ISIN US60770K1079) trades at EUR 215.28 at Lang & Schwarz on October 21, 2026, at 12:01 p.m. CEST. Oddo BHF raised its Moderna price target from USD 170.00 to USD 251.00 on October 19, 2026, according to MarketScreener.

Revenue remains the near-term test

Moderna reported second-quarter revenue of USD 145.00 million for the period ended June 30, 2026, up 2.00 percent from a year earlier. The company posted a GAAP net loss of USD 782.00 million and GAAP earnings per share of minus USD 1.97 for the quarter, according to Moderna.

Management reiterated its expectation for revenue growth of up to 10.00 percent in fiscal year 2026. That outlook places the upcoming seasonal sales period at the center of the valuation debate.

Three milestones shaped the stock

On August 19, 2026, Moderna and Merck said their intismeran cancer treatment met Phase 3 melanoma goals, including a 49.00 percent reduction in recurrence or death, as Yahoo Finance reported. On October 1, 2026, the company announced Nasdaq-100 inclusion beginning October 9, 2026, according to StockTitan. On October 19, 2026, Oddo BHF set the USD 251.00 target.

Which dates matter next?

Detailed melanoma-study data are scheduled for October 24, 2026, at the ESMO Congress, according to Yahoo Finance. Moderna is scheduled to report third-quarter 2026 results on November 6, 2026, with its conference call at 8:00 a.m. ET, according to StockTitan.

What does the target signal?

The USD 251.00 target points to the importance of Moderna's oncology pipeline in current expectations, while the latest quarter still showed a USD 782.00 million GAAP loss. The next results will test whether seasonal vaccine revenue can support the company's fiscal year 2026 growth outlook.

Stock view and company facts

Moderna is developing mRNA medicines across infectious diseases, cancer, rare diseases and autoimmune conditions. Its current market story therefore combines a USD 145.00 million quarterly revenue base with clinical milestones that could broaden the product pipeline.

The stock stood at EUR 215.28 at Lang & Schwarz on October 21, 2026, at 12:01 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.